Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249346 | 1.00 | HPGD (0.63) | HPGDLMNAMAPK1CES2CES1 | |
| SCHEMBL13849535 | 1.00 | HPGD (0.63) | HPGDLMNAMAPK1CES2CES1 | |
| SCHEMBL8208706 | 0.84 | TRPA1 (0.50) | HPGDLMNAMAPK1KDM4EALDH1A1 | |
| Phenylethyl Alcohol SCHEMBL8206256 | 0.83 | TDP1 (0.55) | HPGDLMNAMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL4882534 | 0.79 | LMNA (0.56) | HPGDLMNAMAPK1CES2CES1 | |
| SCHEMBL4525849 | 0.79 | LMNA (0.56) | HPGDLMNAMAPK1CES2CES1 | |
| SCHEMBL4104447 | 0.78 | CYP3A4 (0.47) | HPGDLMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2242532 | 0.78 | CYP3A4 (0.47) | HPGDLMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL18419227 | 0.78 | HPGD (1.00) | HPGDLMNAMAPK1CES2CES1 | |
| SCHEMBL9806266 | 0.77 | HPGD (0.48) | HPGDLMNAKDM4EADRA2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627178-B1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2627178-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2012051036-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| US-7482487-B2 | Phenylaminoethanol derivatives as β2 receptor agonists | PFIZER INC (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | BROWN ALAN D | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, NR3C2, HRH1 | HPGD 290/4885LMNA 3867/4885MAPK1 894/4885 |
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGD 19/4885LMNA 1347/4885MAPK1 1907/4885 |
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | ADRB2, ADRB1, ADRA2C | HPGD 669/4885LMNA 2067/4885MAPK1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.